[Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].

医学 肝细胞癌 肝功能 不良事件通用术语标准 内科学 胃肠病学 肝功能检查 阶段(地层学) 肝硬化 不利影响 肝损伤 古生物学 生物
作者
Ruopeng Li,W L Li,Guosheng Yuan,Hongshen Pang,Q Li,Xiaoyun Hu,Yabing Guo,J Z Chen,Meirong Zang
出处
期刊:PubMed 卷期号:31 (11): 1163-1168
标识
DOI:10.3760/cma.j.cn501113-20230827-00070
摘要

Objective: To compare the postoperative liver function injury condition in patients with intermediate-and advanced-stage hepatocellular carcinoma (HCC) treated with hepatic artery infusion chemotherapy (HAIC) and hepatic artery chemoembolization (TACE) combined with immune checkpoint inhibitors (ICIs) and multi-target tyrosine kinase inhibitors (TKIs). Methods: Patients with intermediate-and advanced-stage HCC who were admitted and treated with HAIC/TACE+ICIs+TKIs therapy at Nanfang Hospital of Southern Medical University from January 2019 to November 2021, with follow-up up to July 2023, were retrospectively enrolled. The results of liver function tests within one week before interventional surgery and on the first day after surgery were recorded. The degree of postoperative liver injury was graded according to the common terminology criteria for adverse events 5.0 (CTCAE 5.0). The treatment efficacy was evaluated according to RECIST 1.1 criteria. Measurement data were compared between groups using a t-test or a non-parametric rank sum test. Enumeration data were compared between the groups using the χ(2) test or Fisher's exact probability method. The survival condition differences were analyzed by the log-rank method. Results: This study included 82 and 77 cases in the HAIC and TACE groups. There were no statistically significant differences between the two groups of patients in terms of gender, age, physical condition score, number of tumors, presence or absence of liver cirrhosis, Child-Pugh grade, albumin-bilirubin (ALBI) grade, and combined ICIs and TKIs . The HAIC group had later tumor staging, a greater tumor burden, poorer liver reserve function, and a larger proportion of patients in stage C (81.7% vs. 63.6%), χ(2)=6.573, P = 0.01). There were 53 cases (64.6% vs. 32.5%) with a maximum tumor diameter of ≥ 10cm, χ(2)=16.441, P < 0.001), and more patients had a retention rate of ≥ 10% for indocyanine green (ICG) at 15 minutes (68.3% vs. 51.9%, P = 0.035). The postoperative incidence rate of increased levels of alanine aminotransferase, aspartate aminotransferase, and total bilirubin was significantly lower in the HAIC group than that in the TACE group (28.0% vs. 63.6%, χ(2)=20.298, P < 0.001, 54.9% vs. 85.7%, χ(2)=17.917, P < 0.001;40.2% vs. 55.8%, χ(2)=3.873, P = 0.049). The number of patients with postoperative ALBI grade 3 was significantly lower in the HAIC group than that in the TACE group (6.1% vs. 16.9%, χ(2)=4.601, P = 0.032). There was no statistically significant difference in the incidence rate of postoperative hypoalbuminemia, activated partial thromboplastin time, or increased international standardized ratio between the two groups of patients. There was no statistically significant difference in median progression-free survival (7.3 months vs. 8.2 months, P = 0.296) or median overall survival (16.5 months vs. 21.9 months, P = 0.678) between the two groups of patients. Conclusion: The incidence rate of postoperative liver injury is higher in patients with intermediate-and advanced-stage HCC treated with TACE combined with ICIs and TKIs than in patients with HAIC combined with ICIs and TKIs.目的: 对比分析肝动脉灌注化疗术(HAIC)和经动脉插管化疗栓塞术(TACE)联合免疫检查点抑制剂(ICIs)和多靶点酪氨酸激酶抑制剂(TKIs)治疗中晚期肝细胞癌(HCC)患者术后肝功能损伤的情况。 方法: 回顾性纳入2019年1月至2021年11月收治于南方医科大学南方医院行HAIC/TACE+ICIs+TKIs治疗的中晚期HCC患者,随访截至2023年7月。记录介入术前1周内及术后第1天肝功能检查结果,根据常见不良反应事件评价标准(CTCAE) 5.0对术后肝损伤程度进行分级,参照实体肿瘤的反应评价1.1标准进行疗效评估。计量资料组间数据比较采用t检验或非参数秩和检验;计数资料组间数据比较采用χ(2)检验或Fisher精确概率法;采用Log-rank法分析生存情况的差异。 结果: 研究纳入HAIC组82例患者,TACE组77例。两组患者的性别、年龄、体力状态评分、肿瘤数量、有无肝硬化、Child-Pugh分级、白蛋白-胆红素(ALBI)分级及联合的ICIs和TKIs方案差异无统计学意义。HAIC组患者肿瘤分期更晚,肿瘤负荷更重,肝储备功能更差,BCLC分期C期患者比例更高(81.7%与63.6%,χ(2)=6.712,P = 0.01),肿瘤最大直径≥10 cm的患者有53例(64.6%与32.5%,χ(2)=16.441,P < 0.001),吲哚菁绿(ICG)15 min滞留率≥10%的患者更多(68.3%与51.9%,P = 0.035)。HAIC组术后丙氨酸转氨酶、天冬氨酸转氨酶、总胆红素水平升高的发生率均显著低于TACE组,分别为28.0%与63.6%,χ(2)=20.298,P < 0.001;54.9%与85.7%,χ(2)=17.917,P < 0.001;40.2%与55.8%,χ(2)=3.873,P = 0.049。HAIC组术后ALBI分级为3级的患者显著少于TACE组(6.1%与16.9%,χ(2)=4.601,P = 0.032)。两组患者术后低白蛋白血症、活化部分凝血活酶时间和国际标准化比值升高的发生率差异无统计学意义。两组患者中位无进展生存期(7.3个月与8.2个月,P = 0.296)及中位总生存期(16.5个月与21.9个月,P = 0.678)差异无统计学意义。 结论: TACE联合ICIs和TKIs治疗中晚期HCC患者术后肝损伤发生率高于HAIC联合ICIs和TKIs治疗。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助左肩微笑采纳,获得10
刚刚
1秒前
1秒前
辛某发布了新的文献求助10
1秒前
吴军霄完成签到,获得积分10
2秒前
3秒前
豆豆完成签到 ,获得积分10
4秒前
展希希发布了新的文献求助10
4秒前
万能图书馆应助缥缈冬寒采纳,获得10
4秒前
vv发布了新的文献求助10
5秒前
汉堡包应助chiweiyoung采纳,获得10
5秒前
7秒前
8秒前
一支布洛芬完成签到,获得积分20
8秒前
8秒前
香蕉觅云应助英俊白莲采纳,获得10
8秒前
英俊的铭应助树精采纳,获得10
10秒前
Ava应助yummy采纳,获得10
10秒前
YJ888发布了新的文献求助10
10秒前
可爱的函函应助lzx采纳,获得10
12秒前
12秒前
gulllluuuukk完成签到,获得积分10
14秒前
Lynn怯霜静完成签到,获得积分10
15秒前
科研通AI5应助青青子衿采纳,获得10
16秒前
孙燕应助lalala采纳,获得50
16秒前
17秒前
17秒前
斯文念波发布了新的文献求助10
18秒前
21秒前
辛某完成签到,获得积分10
21秒前
香蕉觅云应助期刊采纳,获得50
22秒前
22秒前
22秒前
chiweiyoung发布了新的文献求助10
22秒前
无花果应助YJ888采纳,获得10
23秒前
24秒前
24秒前
认真初之发布了新的文献求助10
26秒前
成就茗发布了新的文献求助10
27秒前
一叶舟完成签到 ,获得积分10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989550
求助须知:如何正确求助?哪些是违规求助? 3531774
关于积分的说明 11254747
捐赠科研通 3270278
什么是DOI,文献DOI怎么找? 1804966
邀请新用户注册赠送积分活动 882125
科研通“疑难数据库(出版商)”最低求助积分说明 809176